Sucampo Pharma’s Amitiza receives NICE recommendation
Sucampo CEO Peter Greenleaf said that with more than eight million prescriptions dispensed globally over the past eight years, Amitiza has demonstrated to be an effective treatment option
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.